acumen pharmaceuticals on monday said it commenced an underwritten public offering of 100 million shares of its common stock the charlottesville va clinicalstage biopharmaceutical company said it intends to use proceeds from the offering primarily to fund the phase 2 portion of a future potential phase 23 trial of acu193 to fund research and development and for working capital and other general corporate purposes shares edged down 69 to 905 in aftermarket trading reversing gains made earlier in the day the stock closed up 55 and hit a 52week high on the heels of a strong showing by its acu193 therapy in a phase 1 study in early alzheimers disease